Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 14/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897766 | 0.91 | CETP (0.49) | CETP | |
| SCHEMBL5671037 | 0.90 | LMNA (0.46) | CETPLMNASMN1; SMN2PTGES | |
| SCHEMBL1900110 | 0.89 | CETP (0.49) | CETPPTGDR2TBXA2RPTGDRLMNA | |
| SCHEMBL1897352 | 0.87 | CETP (0.46) | CETP | |
| SCHEMBL1898242 | 0.87 | CETP (0.47) | CETP | |
| SCHEMBL1899307 | 0.87 | DUSP3 (0.37) | CETPSMN1; SMN2PTGES | |
| SCHEMBL1902763 | 0.86 | DUSP3 (0.39) | CETPPTGDR2TBXA2RPTGDRLMNA | |
| SCHEMBL1902779 | 0.86 | HTT (0.39) | LMNASMN1; SMN2PTGES | |
| SCHEMBL1901365 | 0.85 | LOXL2 (0.40) | LMNASMN1; SMN2 | |
| SCHEMBL1898579 | 0.84 | ALDH1A1 (0.42) | CETPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2319509-A1 | Method of Inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-11 | — | — | EP | disclosed |
| EP-2316447-A1 | Method of inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | CETP 1/4885PTGDR2 4089/4885TBXA2R 1476/4885 |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CETP 1/4885PTGDR2 4089/4885TBXA2R 1476/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | CETP 1/4885PTGDR2 4119/4885TBXA2R 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.